Merck (MRK) Wins FDA Approval For First Once Daily Oral PCSK9 Drug

• Merck (NYSE:MRK) has received FDA approval for Lipfendra, the first once daily oral PCSK9 inhibitor for lowering LDL cholesterol.
• Lipfendra offers an oral alternative to existing injectable PCSK9 therapies and adds a new product to Merck's cardiovascular portfolio.
• The approval comes as Merck prepares for major patent expirations and looks to broaden its treatment options for high cholesterol.

For investors watching Merck, the Lipfendra approval lands at a time when the stock is trading around $127.5 and has posted a return of 19.8% year to date. Over the past year, NYSE:MRK is up 64.8%, with a 10.4% gain over the past month and 3.2% over the past week, highlighting recent interest in the company. Lipfendra adds another piece to a product mix that is under close scrutiny as existing blockbusters move closer to patent cliffs.

This new oral PCSK9 option could expand Merck's reach in cholesterol management by providing patients and physicians with a different format compared with injectables. For shareholders, a key consideration will be how Lipfendra’s clinical profile translates into prescription uptake and revenue contribution as Merck reshapes its pipeline for the coming decade.

Stay updated on the most important news stories for Merck by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Merck.

2 things going right for Merck that this headline doesn't cover.

For Merck, Lipfendra’s approval sits at the intersection of medical need, patient convenience, and portfolio timing. PCSK9 drugs from Amgen and Sanofi/Regeneron are already established in cholesterol care but require injections, which can limit use. An oral macrocyclic peptide like Lipfendra gives Merck a way to participate in this class with a format that could appeal to a broader group of patients who are not well controlled on statins or are reluctant to use injectables. That matters as Merck works to diversify earnings ahead of major patent expirations on existing blockbusters.

How This Fits Into The Merck Narrative

• Lipfendra directly supports the narrative that Merck wants more than 20 new growth drivers, adding a cardiometabolic pillar alongside oncology and vaccines.
• Pricing and reimbursement for a first oral PCSK9 could still face pressure, which ties back to concerns in the narrative about drug pricing reform and competition in key markets.
• The narrative focuses heavily on oncology and vaccines, so the scale and timing of a potential cholesterol franchise from Lipfendra may not be fully reflected in that story yet.

Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Merck to help decide what it's worth to you.

The Risks and Rewards Investors Should Consider

• ⚠️ Merck carries a high level of debt, which can limit flexibility if Lipfendra or other launches do not perform as expected.
• ⚠️ Profit margins of 13.6% are lower than 27.3% last year, so investors may question how quickly new products like Lipfendra can support margin rebuilding.
• 🎁 Merck is trading at 41% below one estimate of fair value, and products such as Lipfendra sit within that broader potential upside case.
• 🎁 Earnings are forecast to grow 20.99% per year, and an approved oral PCSK9 therapy gives Merck another asset that could contribute to that growth path.

What To Watch Going Forward

From here, investors watching Merck may want to track how quickly Lipfendra is adopted by physicians relative to existing injectable PCSK9 drugs and high-intensity statins, how payers treat pricing and access for an oral PCSK9, and any early readouts from the ongoing cardiovascular outcomes trial that is testing whether LDL lowering translates into fewer events. It will also be important to see how Merck balances launch investments for Lipfendra with its broader pipeline, particularly KEYTRUDA lifecycle work and other cardiometabolic projects, as the company prepares for upcoming loss of exclusivity events.

To ensure you're always in the loop on how the latest news impacts the investment narrative for Merck, head to the community page for Merck to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com